Acurian Appoints Melissa Cook as Newest Clinical Trial Liaison (CTL) for Its Specialized Cancer Trial Enrollment Support S

HORSHAM, Pa.--(BUSINESS WIRE)-- Acurian, Inc., a leading, full-service provider of global patient recruitment and retention solutions, announced today the appointment of Melissa Cook as its newest Clinical Trial Liaison (CTL) team member. She joins a group dedicated to providing specialized, localized and personalized service for oncology trial patient enrollment.

Acurian created its CTL offering based on extensive research that found while most local physicians and advocacy groups are interested in cancer research, 50-70% never discuss clinical trials as a treatment option. Many cite the disparity between interest and actual involvement as being a result of the time required for physician and staff in maintaining awareness of local trial options. To address this critical need, Acurian CTLs provide on-site education and awareness to promote better understanding of local trial opportunities.

Cook, based in Seattle, WA, is responsible for actively engaging physicians, advocacy groups and other stakeholders in a discussion of the science behind a sponsor’s specific clinical study (conducted at a local trial site).

In positions of increasing responsibility, Melissa has been active in research, sales and marketing roles since 2001. Each has had a focus on close client interaction in the life science, pharmaceutical, biotechnical and oncology sectors. She has a diverse background in each of the aforementioned areas, as well as a strong understanding of business planning, relationship building, and account management.

Cook holds both a Master of Science (Cell and Molecular Biology) and a Bachelor of Science from Virginia Tech. Her career has included specialized sales duties with Integrated DNA Technologies, Inc., Fisher Healthcare, and Bayer Healthcare. In the four years prior to joining the team at Acurian, Cook worked at Xceed Molecular on the development and clinical validation of gene expression biomarkers in various areas of cancer.

“Melissa is a wonderful addition to our expanding CTL team,” said Edwin Watson, Senior Director, Oncology Services at Acurian. “As an oncology professional, she exemplifies the type of individual that defines our CTL program. Our goal is to place more team members just like her in strategic geographic areas around the country.”

About Acurian

Acurian is a leading full-service provider of clinical trial patient recruitment and retention solutions for the life sciences industry. Through its proprietary patient panel of over 65 million patients, centralized advertising capabilities, and a fully hosted enrollment management technology platform, Acurian is able to identify, contact, prescreen, and refer patients into clinical trials, all while supporting investigator sites with services to maximize the randomization potential of every referred patient. Since 1998, Acurian has supported over 400 protocols for more than 60 companies. Acurian's investors include Euclid SR Partners, ProQuest Investments, JP Morgan Partners, Flatiron Partners, CDP Capital Technology Ventures, and Merck Capital Ventures.



CONTACT:

Acurian, Inc.
Scott Connor, Vice President, Marketing, 215-323-9028
[email protected]

KEYWORDS:   United States  North America  Pennsylvania

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Oncology  Pharmaceutical  Other Health  Research  Science  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.